- Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody™ technology to create new immune-stimulating antibody conjugates (ISACs)
- Innovent will pay Bolt an upfront payment and fund development through clinical proof of concept
- Innovent has rights to all programs in Greater China, and both parties have options to participate in full development and commercialization for various regions
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs
Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody™ technology to create new immune-stimulating antibody conjugates (ISACs)
Innovent
Related Posts
AMMO Reiterates FY23 Guidance
Reiterating Fiscal Year 2023 Guidance
Total Revenues of $300 million to $310 million
EBITDA of $82 million to $85 million
Adjusted EBITDA of $108
Worksport Launches Storefronts On Amazon, eBay And Walmart Marketplace
Worksport Ltd (NASDAQ:WKSP) has launched its eCommerce storefronts on Amazon.com (NASDAQ:AMZN), eBay (NASDAQ:EBAY), and Walmart (NYSE:WMT) Marketplace. N.A. Williams Company will execute Worksport’s marketing campaigns on each platform…
United States Geological Survey Awards Teledyne Marine $16M IDIQ Contract
Teledyne Marine, a business unit of Teledyne Technologies Incorporated (NYSE:TDY) and a leading supplier of marine technology, has received an Indefinite Delivery/Indefinite Quantity (IDIQ) contract from the United